BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, DBA UNIVERSITY OF CALIFORNIA IRVINE MEDICAL CENTER, Terry Belmont-Chief Operating Officer Original Hospital Pharmacy Permit Number HPE 49819 Sterile Compounding Permit Number LSE 100230;

KATHERINE Y. BOHENEK,
Pharmacist License Number RPH 49572;

DANIEL PHUONG HOANG,
Pharmacist License Number 59004;

SHIKHA SANJIV PARIKH,
Pharmacist License Number RPH 72781;

KEVIN M. KONG,
Pharmacist License Number RPH 39458;

and

MELANIE DENISE JOE,
Pharmacist License Number RPH 49712

PAGE 1

Respondents.

Agency Case No. 6997

OAH No. 2021030749

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order for Public Reproval is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on January 5, 2022.

It is so ORDERED on December 6, 2021.

BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

Seung W. Oh, Pharm.D.

Board President

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	ROB BONTA Attorney General of California GREGORY J. SALUTE Supervising Deputy Attorney General SHANNON M. BRUBAKER Deputy Attorney General State Bar No. 234517 600 West Broadway, Suite 1800 San Diego, CA 92101 P.O. Box 85266 San Diego, CA 92186-5266 Telephone: (619) 738-9078 Facsimile: (619) 645-2061 Attorneys for Complainant BEFOR BOARD OF I DEPARTMENT OF CONTROL OF CALIFORNIA, DBA UNIVERSITY OF CALIFORNIA	PHARMACY ONSUMER AFFAIRS
17 18 19 20	Bldg. 23, 2nd Floor 101 The City Drive, Rt. 32, Bldg. 23 Orange, CA 92868 Original Hospital Pharmacy Permit Number HPE 49819 Sterile Compounding Permit Number LSE 100230,	REGENTS OF THE UNIVERSITY OF CALIFORNIA, DBA UNIVERSITY OF CALIFORNIA IRVINE MEDICAL CENTER ONLY [Bus. & Prof. Code § 495]
21 22	KATHERINE Y. BOHENEK 24 Flores Foothill Ranch, CA 92610	
23	Pharmacist License Number RPH 49572,	
2425	DANIEL PHUONG HOANG 26 Lupari Irvine, CA 92618	
26	Pharmacist License Number RPH 59004,	
27		
28		

1 2 3	SHIKHA SANJIV PARIKH 96 Desert Pine Irvine, CA 92620 Pharmacist License Number RPH 72781,
4	KEVIN M. KONG 39 Climbing Vine Irvine, CA 92603-9497
5	Pharmacist License Number RPH 39458,
6	and
7	MELANIE DENISE JOE
9	101 The City Drive South Rt. 32 – Pharmacy Orange, CA 92868
10	Pharmacist License Number RPH 49712
11	Respondents.
12	
13	IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
14	entitled proceedings that the following matters are true:
15	<u>PARTIES</u>
16	1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy
17	(Board). She brought this action solely in her official capacity and is represented in this matter by
18	Rob Bonta, Attorney General of the State of California, by Shannon M. Brubaker, Deputy
19	Attorney General.
20	2. Respondent The Regents of the University of California, doing business as University
21	of California Irvine Medical Center (Respondent) is represented in this proceeding by attorneys
22	Jordan Keville and Christine Johnson of Davis Wright Tremaine LLP whose address is: 865 S.
23	Figueroa Street, Suite 2400, Los Angeles, California 90017.
24	<u>JURISDICTION</u>
25	3. On or about December 22, 2008, the Board issued Original Hospital Pharmacy Permit
26	Number HPE 49819 to Respondent. The Original Hospital Pharmacy Permit was in full force
27	and effect at all times relevant to the charges brought herein and will expire on July 1, 2022,

unless renewed.

- 4. On or about June 19, 2014, the Board issued Sterile Compounding Permit Number LSE 100230 to Respondent. The Sterile Compounding Permit was in full force and effect at all times relevant to the charges brought herein and will expire on July 1, 2022, unless renewed.
- 5. Accusation Number 6997 was filed before the Board and is currently pending against Respondent. The Accusation and all other statutorily required documents were properly served on Respondent on December 1, 2020. Respondent timely filed its Notice of Defense contesting the Accusation. A copy of Accusation Number 6997 is attached as Exhibit A and incorporated herein by reference.

ADVISEMENT AND WAIVERS

- 6. Respondent has carefully read, fully discussed with counsel, and understands the charges and allegations in Accusation Number 6997. Respondent has also carefully read, fully discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary Order for Public Reproval.
- 7. Respondent is fully aware of its legal rights in this matter, including the right to a hearing on the charges and allegations in the Accusation; the right to confront and cross-examine the witnesses against it; the right to present evidence and to testify on its own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.
- 8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.

CULPABILITY

- 9. Respondent understands and agrees that the charges and allegations in Accusation Number 6997, if proven at a hearing, constitute cause for imposing discipline upon its Original Hospital Pharmacy Permit and Sterile Compounding Permit.
- 10. For the purpose of resolving the Accusation without the expense and uncertainty of further proceedings, Respondent agrees that, at a hearing, Complainant could establish a factual ///

basis for the charges in Accusation Number 6997, and that Respondent hereby gives up its right to contest those charges.

- 11. Respondent agrees that in any future disciplinary proceeding before the Board against Respondent, the allegations set forth in Accusation Number 6997 shall be deemed admitted.
- 12. Respondent agrees that its Original Hospital Pharmacy Permit and Sterile Compounding Permit are subject to discipline, and it agrees to be bound by the Disciplinary Order below.

CONTINGENCY

- 13. This stipulation shall be subject to approval by the Board. Respondent understands and agrees that counsel for Complainant and the staff of the Board may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondent or its counsel. By signing the stipulation, Respondent understands and agrees that it may not withdraw its agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order for Public Reproval shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.
- 14. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order for Public Reproval, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.
- 15. This Stipulated Settlement and Disciplinary Order for Public Reproval is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order for Public Reproval may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.

///

16. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

DISCIPLINARY ORDER

IT IS HEREBY ORDERED that Original Hospital Pharmacy Permit Number HPE 49819 and Sterile Compounding Permit Number LSE 100230 issued to Respondent The Regents of the University of California, doing business as University of California Irvine Medical Center (Respondent) shall be publicly reproved by the Board of Pharmacy under Business and Professions Code section 495 in resolution of Accusation Number 6997, attached as Exhibit A. This Decision constitutes a record of discipline and shall become a part of Respondent's license history with the Board.

Cost Recovery. Within one year of the effective date of the Decision, Respondent shall pay \$8,538.88 to the Board for its costs associated with the investigation and enforcement of this matter pursuant to Business and Professions Code Section 125.3. Respondent shall be permitted to pay these costs in a payment plan approved by the Board. If Respondent fails to pay the Board costs as ordered, Respondent shall not be allowed to renew its Original Hospital Pharmacy Permit and Sterile Compounding Permit until Respondent pays costs in full.

Full Compliance. As a resolution of the charges in Accusation Number 6997, this stipulated settlement is contingent upon Respondent's full compliance with all conditions of this Order. If Respondent fails to satisfy any of these conditions, such failure to comply constitutes cause for discipline, including outright revocation, of Respondent's Original Hospital Pharmacy Permit Number HPE 49819 and Sterile Compounding Permit Number LSE 100230.

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order for Public Reproval and have fully discussed it with Respondent's attorneys, Jordan Keville and Christine Johnson. I understand the stipulation and the effect it will have on Respondent's Original Hospital Pharmacy Permit and Sterile Compounding Permit. I am authorized to enter the stipulation on behalf of Respondent and enter into this Stipulated Settlement and Disciplinary

1	Order for Public Reproval voluntarily, knowingly, and intelligently. Respondent agrees to be	
2	bound by the Decision and Order of the Board of Pharmacy.	
3		
4	DATED:	
5	CHAD LEFTERIS As the Authorized Representative of	
6	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, DBA UNIVERSITY OF	
7	CALIFORNIA IRVINE MEDICAL CENTER Respondent	
8	Tesponaen.	
9	I have read and fully discussed with Respondent the terms and conditions and other matter	
10	contained in the above Stipulated Settlement and Disciplinary Order for Public Reproval. I	
11	approve its form and content.	
12		
13	DATED: JORDAN KEVILLE	
14	CHRISTINE JOHNSON Attorneys for Respondent	
15		
16	<u>ENDORSEMENT</u>	
17	The foregoing Stipulated Settlement and Disciplinary Order for Public Reproval is hereby	
18	respectfully submitted for consideration by the Board of Pharmacy, Department of Consumer	
19	Affairs.	
20		
21	DATED: Respectfully submitted,	
22	ROB BONTA Attorney General of California	
23	GREGORY J. SALUTE Supervising Deputy Attorney General	
24		
25	Shannon M. Brubaker	
26	Deputy Attorney General Attorneys for Complainant	
27	SD2020800691 / 83090789.docx	
28		
	6	

	1	
1	Order for Public Reproval voluntarily, knowingly, and intelligently. Respondent agrees to be	
2	bound by the Decision and Order of the Board of Pharmacy.	
3 4	DATED: 10/15/2021	
5	CHAD LEFTERIS As the Authorized Representative of	
6	THE REGENTS OF THE UNIVERSITY OF	
7	CALIFORNIA, DBA UNIVERSITY OF CALIFORNIA IRVINE MEDICAL CENTER Respondent	
8		
9	I have read and fully discussed with Respondent the terms and conditions and other matter	
10	contained in the above Stipulated Settlement and Disciplinary Order for Public Reproval. I	
11	approve its form and content.	
12	1.10.12.11	
13	DATED: 10/16/2021 JOHN KEVILLE	
14	CHRISTINE JOHNSON Attorneys for Respondent	
15	Autorneys for Respondent	
16	<u>ENDORSEMENT</u>	
17	The foregoing Stipulated Settlement and Disciplinary Order for Public Reproval is hereby	
18	respectfully submitted for consideration by the Board of Pharmacy, Department of Consumer	
19	Affairs.	
20		
21	DATED: October 18, 2021 Respectfully submitted,	
22	ROB BONTA	
23	Attorney General of California GREGORY J. SALUTE	
24	Supervising Deputy Attorney General	
25		
26	SHANNON M. BRUBAKER Deputy Attorney General	
27	Attorneys for Complainant	
28	SD2020800691 / 83090789.docx	
- 11		

Exhibit A

Accusation Number 6997

1	XAVIER BECERRA	
2	Attorney General of California MARICHELLE S. TAHIMIC	
3	Supervising Deputy Attorney General BRIAN WEISEL	
4	Deputy Attorney General State Bar Number 251111	
5	600 West Broadway, Suite 1800 San Diego, CA 92101	
6	P.O. Box 85266 San Diego, CA 92186-5266	
7	Telephone: (619) 738-9089 Facsimile: (619) 645-2061	
8	E-mail: Brian.Weisel@doj.ca.gov Attorneys for Complainant	
9		
10		RE THE PHARMACY
11	DEPARTMENT OF C STATE OF C	ONSUMER AFFAIRS ALIFORNIA
12		
13	In the Matter of the Accusation Against:	Case Number 6997
14	THE REGENTS OF THE UNIVERSITY	Cuse Ivallioer 0777
15	OF CALIFORNIA, DBA UNIVERSITY OF CALIFORNIA	ACCUSATION
16	IRVINE MEDICAL CENTER, Terry Belmont – Chief Operating Officer	Necesimon
17	Bldg. 23, 2nd Floor 101 The City Drive, Rt. 32, Bldg. 23	
18	Orange, CA 92868	
19	Original Hospital Pharmacy Permit Number HPE 49819	
20	Sterile Compounding Permit Number LSE 100230,	
21	KATHERINE Y. BOHENEK	
22	24 Flores Foothill Ranch, CA 92610	
23	Pharmacist License Number RPH 49572,	
24	DANIEL PHUONG HOANG	
25	26 Lupari Irvine, CA 92618	
26	Pharmacist License Number RPH 59004,	
27		
28		4

1 2 3 4 5 6 7 8 9	SHIKHA SANJIV PARIKH 96 Desert Pine Irvine, CA 92620 Pharmacist License Number RPH 72781, KEVIN M. KONG 39 Climbing Vine Irvine, CA 92603-9497 Pharmacist License Number RPH 39458, and MELANIE DENISE JOE 101 The City Drive South Rt. 32 - Pharmacy Orange, CA 92868
11	Pharmacist License Number RPH 49712
12	Respondents.
13	
14	<u>PARTIES</u>
15	1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity
16	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs (Board).
17	2. On or about December 22, 2008, the Board issued Original Hospital Pharmacy Permi
18	Number HPE 49819 to The Regents of the University of California, doing business as the
19	University of California Irvine Medical Center (Respondent UCIMC). The Original Hospital
20	Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein
21	and will expire on July 1, 2021, unless renewed.
22	3. On or about June 19, 2014, the Board issued Sterile Compounding Permit Number
23	LSE 100230 to Respondent UCIMC. The Sterile Compounding Permit was in full force and
24	effect at all times relevant to the charges brought herein and will expire on July 1, 2021, unless
25	renewed.
26	4. On or about August 21, 1997, the Board issued Pharmacist License Number RPH
27	49572 to Katherine Y. Bohenek (Respondent Bohenek). The Pharmacist License was in full force
28	2

and effect at all times relevant to the charges brought herein and will expire on November 30, 2020, unless renewed.

- 5. On or about October 17, 2006, the Board issued Pharmacist License Number RPH 59004 to Daniel Phuong Hoang (Respondent Hoang). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on April 30, 2022, unless renewed.
- 6. On or about July 9, 2015, the Board issued Pharmacist License Number RPH 72781 to Shikha Sanjiv Parikh (Respondent Parikh). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on June 30, 2021, unless renewed.
- 7. On or about August 27, 1985, the Board issued Pharmacist License Number RPH 39458 to Kevin M. Kong (Respondent Kong). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on August 31, 2021, unless renewed.
- 8. On or about August 27, 1997, the Board issued Pharmacist License Number RPH 49712 to Melanie Denise Joe (Respondent Joe). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on September 30, 2021, unless renewed.

JURISDICTION

- 9. This Accusation is brought before the Board, under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.
- 10. Section 4011 of the Code provides that the Board shall administer and enforce both the Pharmacy Law [Code section 4000 et seq.] and the Uniform Controlled Substances Act [Health & Safety Code section 11000 et seq.].
- 11. Section 4032 defines "license" to include any license, permit, registration, certificate or exemption issued by the Board.

///

1	17. Section 4127.1, subdivision (f), of the Code states:	
2	Adverse effects reported or potentially attributable to a pharmacy's sterile drug product shall be reported to the board within 12 hours and immediately reported to the MedWatch program of the federal Food and Drug Administration.	
3		
4	18. Section 4301 of the Code states:	
5	The board shall take action against any holder of a license who is guilty of	
6	unprofessional conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:	
7	•••	
8	(b) Incompetence	
9		
10	(j) The violation of any of the statutes of this state, of any other state, or of the United States regulating controlled substances and dangerous drugs.	
11	the Office States regulating controlled substances and dangerous drugs.	
12	•••	
13	(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this	
14	chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or	
15	federal regulatory agency.	
16	•••	
17	19. California Code of Regulations, Title 16, section 1761, states:	
18	(a) No pharmacist shall compound or dispense any prescription which contains any significant error, omission, irregularity, uncertainty, ambiguity or	
19	alteration. Upon receipt of any such prescription, the pharmacist shall contact the prescriber to obtain the information needed to validate the prescription.	
20		
21		
22	COST RECOVERY	
23	20. Section 125.3 of the Code states, in pertinent part, that the Board may request the	
24	administrative law judge to direct a licentiate found to have committed a violation or violations of	
25	the licensing act to pay a sum not to exceed the reasonable costs of the investigation and	
26	enforcement of the case.	
27		
28	6	

DEFINITIONS

- 21. <u>Etoposide</u>, sold under the brand name Vepesid or Etopophos, is a chemotherapy medication used for the treatments of a number of types of cancer.
- 22. <u>Intrathecal Administration</u> is a route of drug administration directly into the spinal canal, so that it reaches the cerebrospinal fluid, which is sometimes used for administration of chemotherapy or anesthesia.

FACTUAL ALLEGATIONS

- 23. At all times relevant herein, Respondents Bohenek, Hoang, and Joe were employed as licensed pharmacists for the University of California, Irvine Medical Center (Respondent UCIMC). Respondent Joe was the pharmacist in charge of the UCIMC hospital pharmacy.
- 24. In 2013, Patient J.A. was diagnosed with Medulloblastoma (commonly known as a brain tumor). Patient J.A. received Radiosurgery in August 2017. On or about July 27, 2017, Patient J.A. also began a cycle of intrathecal chemotherapy through Respondent UCIMC.
- 25. Sometime between July and November, 2017, UCIMC converted its pharmacy software program from "AllScript" to the "EPIC" software program. Part of this transition included the pharmacist manually entering the previous prescriptions into the new system.
- 26. Among her chemotherapy treatments, Patient J.A. was prescribed 0.5 mg of intrathecal etoposide. On or about November 14, 2017, during one of her treatments, J.A. received a dosage of 100 mg of intrathecal etoposide, 200 times the prescribed dose. Doses of up to 150 mg of etoposide are not uncommon when given intravenously (IV), but such a dose is orders of magnitude outside the accepted range for spinal administration, which normally falls from ranges of 0.5 mg to 2.5 mg.
- 27. Almost immediately after the November dose, Patient J.A. developed a severe burning headache, nausea, vomiting, dizziness, and restlessness. J.A. was admitted to the hospital and treated for possible chemical meningitis secondary to chemotherapy.
- 28. Approximately three days after the incorrect dosage, J.A. stopped responding to stimulus, became fully non-responsive, and required a ventilator to breathe. J.A.'s condition did not improve, and on April 8, 2018, J.A. was released from life support and died.

- 29. The error in dosage was systemic, requiring numerous checks to be failed before a patient could receive such a high dosage of chemotherapy directly into the spinal canal.
- 30. Respondent Kong incorrectly transferred Patient J.A.'s order from AllScript to EPIC, entering 100 mg intrathecal instead of 0.5 mg intrathecal. The new EPIC program did not have an obvious code for intrathecal administration of the drug; therefore, the transcribing pharmacist used the usual IV code. The transcribing pharmacist, and all subsequent treating pharmacists, should have known that a dose as high as 100 mg was far outside the standard of care for a spinal injection.
- 31. According to the logged initials within the software program, the erroneous prescription was handled by several pharmacists at UCIMC, none of whom questioned the extremely high dosage for spinal injection, specifically:
- Respondent Kong transferred the order from the AllScript program to the EPIC a. program with the incorrect administration procedure, keeping the dosage common for a normal IV treatment, as opposed to a spinal treatment.
 - Respondent Parikh reviewed and verified the treatment plan with the order. b.
 - Respondent Hoang reviewed and verified the treatment plan with the order. c.
- Respondent Bohenek verified the compound preparation and labeling of the e. order.
- f. The EPIC program contained a "detailed" view screen which, if viewed, would have shown the proper route of administration of the drug; however, policy under UCIMC and Respondent Joe did not require the verifying pharmacist to view this data screen to verify the drug delivery method.
- Though Respondent UCIMC reported the above to the California Department of Public Health, none of the Respondents reported the above to the Board until a civil settlement with the family of J.A. was reached nearly one year later, on or about November 30, 2018.

///

///

FIRST CAUSE FOR DISCIPLINE

(Incompetence by Respondent UCIMC)

33. Respondent Regents of California, doing business as University of California Irvine Medical Center, is subject to disciplinary action under Code section 4301, subsection (b), in that it was incompetent when it failed to implement policy to prevent a system failure leading to the excessive and fatal dosage to the patient, as further discussed in paragraphs 23 through 32, which are herein incorporated by reference.

SECOND CAUSE FOR DISCIPLINE

(Unprofessional Conduct by Respondent UCIMC)

34. Respondent Regents of California, doing business as University of California Irvine Medical Center, is subject to disciplinary action under Code section 4306.5, subsections (a) and (b), and California Code of Regulation section 1761, subdivision (a), as the facility's acts or omissions in the administration of etoposide 100 mg intrathecal were an inappropriate exercise of the education, training, or experience as a licensed hospital pharmacy and sterile compounding facility. Further, Respondent UCIMC did not report the adverse effects potentially attributable to the pharmacy's sterile drug product as required in Code section 4127.1(f), as further discussed in paragraphs 23 through 32, above, which are herein incorporated by reference.

THIRD CAUSE FOR DISCIPLINE

(Unprofessional Conduct by Respondent Katherine Y. Bohenek)

35. Respondent Katherine Bohenek is subject to disciplinary action under Code section 4306.5, subsections (a) and (b), and California Code of Regulation section 1761, subdivision (a), in that her acts or omissions in verifying the compounded preparation and labeling of intrathecal etoposide were an inappropriate exercise of her education, training, or experience as a pharmacist, as further discussed in paragraphs 23 through 32, above, which are herein incorporated by reference.

g

--

///

FOURTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct by Respondent Daniel Phuong Hoang)

36. Respondent Daniel Phuong Hoang is subject to disciplinary action under Code section 4306.5, subsections (a) and (b) and California Code of Regulation section 1761, subdivision (a), as his acts or omissions in reviewing and verifying the treatment plan for etoposide 100 mg intrathecal were an inappropriate exercise of his education, training, or experience as a pharmacist, as further discussed in paragraphs 23 through 32, above, which are herein incorporated by reference.

FIFTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct by Shikha Sanjiv Parikh)

37. Respondent Shikha Sanjiv Parikh is subject to disciplinary action under Code section 4306.5, subsections (a) and (b), and California Code of Regulation section 1761, subdivision (a), as her acts or omissions in reviewing and verifying the treatment plan for etoposide 100 mg intrathecal were an inappropriate exercise of her education, training, or experience as a pharmacist, as further discussed in paragraphs 23 through 32, above, which are herein incorporated by reference.

SIXTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct by Respondent Kevin Kong)

38. Respondent Kevin Kong is subject to disciplinary action under Code section 4306.5, subsections (a) and (b), and California Code of Regulation section 1761, subdivision (a), in that his acts or omissions in transferring the order for etoposide from the AllScript program to the EPIC program with the incorrect administration procedure and keeping the dosage common for a normal IV treatment, as opposed to intrathecal administration were an inappropriate exercise of his education, training, or experience as a pharmacist, as further discussed in paragraphs 23 through 32, above, which are herein incorporated by reference.

///

SEVENTH CAUSE FOR DISCIPLINE

(Incompetence by Respondent Melanie Denise Joe)

39. Respondent Melanie Denise Joe is subject to disciplinary action under Code section 4301, subsection (b), in that she was incompetent as pharmacist-in-charge of UCIMC pharmacy when she failed to implement a policy to prevent a system failure leading to the excessive and fatal dosage to the patient, as further discussed in paragraphs 23 through 32, which are herein incorporated by reference.

EIGHTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct by Respondent Melanie Denise Joe)

40. Respondent Melanie Denise Joe is subject to disciplinary action under Code section 4113, subsection (c), 4306.5, subsections (a) and (b), and California Code of Regulation section 1761, subdivision (a), as her acts or omissions as pharmacist-in-charge of UCIMC in dispensing etoposide 100 mg intrathecal were an inappropriate exercise of the education, training, or experience as a licensed pharmacist as further discussed in paragraphs 23 through 32, above, which are herein incorporated by reference.

OTHER MATTERS

- 41. Pursuant to Section 4307, if Original Hospital Pharmacy Permit Number HPE 49819 issued to the Regents of the University of California, doing business as the University of California Irvine Medical Center is suspended, revoked or placed on probation, Respondent UCIMC shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee of the Board.
- 42. Pursuant to Section 4307, if Sterile Compounding Permit Number LSE 100230 issued to the Regents of the University of California, doing business as the University of California Irvine Medical Center is suspended, revoked or placed on probation, Respondent UCIMC shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee of the Board.

- 43. Pursuant to Section 4307, if Pharmacist License Number RPH 49572 issued to Katherine Y. Bohenek is suspended, revoked or placed on probation, Respondent Bohenek shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee of the Board.
- 44. Pursuant to Section 4307, if Pharmacist License Number RPH 59004 issued to Daniel Phuong Hoang is suspended or revoked, Respondent Hoang shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee.
- 45. Pursuant to Section 4307, if Pharmacist License Number RPH 72781 issued to Shikha Sanjiv Parikh is suspended or revoked, Respondent Parikh shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee.
- 46. Pursuant to Section 4307, if Pharmacist License Number RPH 39458 issued to Kevin M. Kong is suspended or revoked, Respondent Kong shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee.
- 47. Pursuant to Section 4307, if Pharmacist License Number RPH 49712 issued to Melanie Denise Joe is suspended or revoked, Respondent Joe shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- Revoking or suspending Original Hospital Pharmacy Permit Number HPE 49819,
 issued to The Regents of the University of California, dba University of California Irvine Medical
 Center;
- 2. Revoking or suspending Sterile Compounding Permit Number LSE 100230, issued to The Regents of the University of California, dba University of California Irvine Medical Center;
- 3. Revoking or suspending Pharmacist License Number RPH 49572, issued to Katherine Y. Bohenek;
- Revoking or suspending Pharmacist License Number RPH 59004, issued to Daniel
 Phuong Hoang;

- 5. Revoking or suspending Pharmacist License Number RPH 72781, issued to Shikha Sanjiv Parikh;
- Revoking or suspending Pharmacist License Number RPH 39458, issued to Kevin M.
 Kong;
- 7. Revoking or suspending Pharmacist License Number RPH 49712, issued to Melanie Denise Joe;
- 8. Prohibiting The Regents of the University of California, dba University of California Irvine Medical Center from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Original Hospital Pharmacy Permit Number HPE 49819 or Sterile Compounding Permit Number LSE 100230 is placed on probation or Original Hospital Pharmacy Permit Number HPE 49819 or Sterile Compounding Permit Number LSE 100230 is reinstated if Original Hospital Pharmacy Permit Number HPE 49819 or Sterile Compounding Permit Number LSE 100230 issued to The Regents of the University of California, dba University of California Irvine Medical Center are revoked;
- 9. Prohibiting Respondent Katherine Y. Bohenek from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist License Number RPH 49572 is placed on probation or until Pharmacist License Number RPH 49572 is reinstated if Pharmacist License Number RPH 49572 issued to Katherine Y. Bohenek is revoked;
- 10. Prohibiting Respondent Daniel Phuong Hoang from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist License Number RPH 59004 is placed on probation or until Pharmacist License Number RPH 59004 is reinstated if Pharmacist License Number RPH 59004 issued to Daniel Phuong Hoang is revoked;
- 11. Prohibiting Respondent Shikha Sanjiv Parikh from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist License Number RPH 72781 is placed on probation or until Pharmacist License